Author

G. Pages

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cancer Biology· 5

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:cancer & tumor microenvironment· 4 Approach:experimental assay· 4 Assay:bulk RNA-seq· 3 Organism:human· 3 Research Focus:differential expression· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Assay:DNA methylation· 1

Frequent Co-Authors

S. GIULIANO· 3 shared J. Durivault· 2 shared M. Dufies· 2 shared M. Pagnuzzi-Boncompagni· 2 shared M. Teisseire· 2 shared R. Grepin· 2 shared V. Picco· 2 shared V. Vial· 2 shared

Activity by Year

2019-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 29 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersCancer Biology

S. GIULIANO

Mutual co-authors in cluster

Author profile →

5 papers

Recent·Most cited

Disrupting USP39 deubiquitinase Function Impairs the Survival and Migration of Multiple Myeloma Cells through ZEB1 Degradation

J. Sirera, S. Sarlak, M. Teisseire, A. Carminati, C. Savy, V. Nicolini, P. Brest, C. Bontoux, M. Deckert, M. Ohanna, S. GIULIANO, M. Dufies, G. Pages, F. Luciano

This study identifies USP39 as a critical survival and migration factor in multiple myeloma cells, showing that its disruption leads to ZEB1 degradation and reduced tumor growth.

bioRxiv · Apr 23, 2024 · PreprintCancer Biology

Exploiting De Novo Serine Synthesis as a Metabolic Vulnerability to Overcome Sunitinib Resistance in Advanced Renal Cell Carcinoma

M. Teisseire, U. Sahu, J. Parola, M.-C. Tsai, V. Vial, J. Durivault, R. Grepin, Y. Cormerais, G. Pages, I. Ben-Sahra, S. Giuliano

This study identifies serine synthesis as a metabolic vulnerability in sunitinib-resistant renal cell carcinoma, showing that inhibiting key enzymes enhances drug sensitivity.

bioRxiv · Mar 22, 2024 · PreprintCancer Biology

The antiangiogenic compound axitinib demonstrates low toxicity and anti-tumoral effects against medulloblastoma

M. Pagnuzzi-Boncompagni, V. Picco, V. Vial, V. Planas-Bielsa, A. Vandenberghe, R. Grepin, J. Durivault, C. Montemagno, S. Martial, J. Doyen, J. Gavard, G. Pages

This study evaluates axitinib's efficacy and safety in medulloblastoma, finding it has low toxicity and anti-tumoral effects in preclinical models and poor prognosis association in public databases.

bioRxiv · Sep 18, 2020 · PreprintCancer Biology

A multi-layered systems approach for renal cell carcinoma

L. Cooley, J. Rudewicz, W. Souleyreau, K. Clarke, F. Falciani, M. Dufies, S. Verbeke, A. Emanuelli, S. Benzekry, C. Taing, E. J. Ribot, S. Miraux, D. Lambrechts, E. Modave, R. Pineau, , A. Bikfalvi

A multi-layered systems approach identifies prognostic and predictive biomarkers for renal cell carcinoma aggressiveness through in vivo models and integrative analysis.

bioRxiv · Jan 13, 2020 · PreprintCancer Biology

Pharmacological inhibition of the amino-acid transporter LAT1 demonstrates in vitro anti-neoplastic activity towards medulloblastoma

Y. Cormerais, M. Pagnuzzi-Boncompagni, S. Schrötter, S. Giuliano, E. Tambutte, H. Endou, M. F. Wempe, G. Pages, J. Pouyssegur, V. Picco

This study shows that JPH203, a LAT1 inhibitor, effectively reduces medulloblastoma cell proliferation and survival without harming normal cells.

bioRxiv · Jan 8, 2019Cancer Biology